{"name":"Guillermo Umpierrez, MD","slug":"guillermo-umpierrez-md","ticker":"","exchange":"","domain":"","description":"Guillermo Umpierrez, MD, is a medical professional with a focus on diabetes management and treatment. The company has developed two marketed drugs, Basal Plus and sliding scale regular insulin (SSRI), aimed at improving patient outcomes in diabetes care.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Basal Plus","genericName":"Basal Plus","slug":"basal-plus","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Basal Plus","genericName":"Basal Plus","slug":"basal-plus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNc0RQcDVWNGNNZmVPb1dlQ3FPM2xvX1RjazFBejVZNE1JSlhpR2J1T3ZwUnJvT3hZbTZhaUpFTDZRRG9qRzIyREFKakNaM3NRUUVNX2tscmxKZno1RkhoTE5sNDFscVJWSEg5aDM0N1hpNGN6RTFHd3FTb0ZFME5WdzZpQVZpbHNQaFNJSDI1T0tUdGlzYVlfVA?oc=5","date":"2019-03-07","type":"pipeline","source":"Science | AAAS","summary":"The war on ‘prediabetes' could be a boon for pharma—but is it good medicine? - Science | AAAS","headline":"The war on ‘prediabetes' could be a boon for pharma—but is it good medicine? - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFJLMzNSOHFwV2stMDEzZ0dtbTh5dENEZFlHeXFnZERCU2JvcVpTQk1pYmppVEZhblZfZVBkODZtdzFad3FxYThkQjBGamdjY2JtS2gzTkRCdlFnSUVSZ3dNZVprRWdma0g2NnpJM0I1M3lxVUJkVDhLTjJXR2c0cGI5RlVlbUdK?oc=5","date":"2018-07-06","type":"pipeline","source":"Emory University","summary":"Endocrinologist honored for outstanding work in diabetes | Emory University | Atlanta GA - Emory University","headline":"Endocrinologist honored for outstanding work in diabetes | Emory University | Atlanta GA","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}